Psilocybin in the News

The latest news about psilocybin for addiction, depression and anxiety

Psychedelic therapy for depression still effective one year later

New research published in the Journal of Psychopharmacology has offered valuable insights into the long-term effects of psilocybin-assisted psychotherapy for depression. The study reports more than half the original cohort were still in remission 12 months after the acute psychedelic treatment.

Source: New Atlas

AL.com

Magic mushrooms: UAB Studying Benefits for Addiction and Pain

Psychedelic drugs creating hopes for breakthroughs in depression, anxiety, pain and addiction are being tested at UAB. The university is one of a handful in the nation conducting trials with psilocybin, the active ingredient in hallucinogenic mushrooms.

Source: AL.com

Vice News

Can 12 Step Groups and Psychedelic Addiction Treatment Coexist?

Psychedelic treatments for addiction challenge 12-step’s ideas about what sobriety is: total abstinence from any mood- or mind-altering drug—psychedelics included.

Source: Vice News

The Independent

Magic mushroom compound provides anti-anxiety and antidepressant effects lasting years, study finds

Single dose of psilocybin leads to decreased demoralisation and improved spiritual wellbeing among cancer sufferers, long-term research indicates.

Source: The Independent

Johns Hopkins

Magic Mushrooms Help Longtime Smokers Quit

Johns Hopkins researchers report that a small number of longtime smokers who had failed many attempts to drop the habit did so after a carefully controlled and monitored use of psilocybin, the active hallucinogenic agent in so-called “magic mushrooms,” in the context of a cognitive behavioral therapy treatment program.

Source: Johns Hopkins

PBS

Treatment with hallucinogenic mushroom drug shows promise for patients with deep anxiety

Two studies published Thursday in the Journal of Psychopharmacology suggest that psilocybin may offer a dramatic helping hand.

Source: PBS

NYU Langone

Mental Health Benefits from One Dose of Psychedelic Drug Last for Years in People with Cancer

Following up on their landmark 2016 study, researchers at NYU Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin, a compound found in psychedelic mushrooms, combined with psychotherapy, appears to be associated with significant improvements in emotional and existential distress in people with cancer

Source: NYU Langone

Scientific American

Johns Hopkins Scientists Give Psychedelics the Serious Treatment

Psychedelic drugs—once promising research subjects that were decades ago relegated to illicit experimentation in dorm rooms—have been steadily making their way back into the lab for a revamped 21st-century-style look. Scientists are rediscovering what many see as the substances’ astonishing therapeutic potential for a vast range of issues, from depression to drug addiction and acceptance of mortality.

Source: Scientific American

BBC

Psilocybin: Magic mushroom compound 'promising' for depression

Psychedelic drug psilocybin, found in magic mushrooms, is as good at reducing symptoms of depression as conventional treatment, a small, early-stage study has suggested.

Source: BBC

Yale News

Psychedelic spurs growth of neural connections lost in depression

In a new study, Yale researchers show that a single dose of psilocybin given to mice prompted an immediate and long-lasting increase in connections between neurons. The findings are published July 5 in the journal Neuron.

Source: Yale News